HLA-DQB1*02 - restricted HPV-16 E7 peptide - specific CD4+ T-Cell immune responses correlate with regression of HPV-16- associated high-grade squamous intraepithelial lesions

Clinical Cancer Research

Volumn 13, Issue 8, 2007, Pages 2479-2487

  Peng, Shiwen ^a   Trimble, Cornelia ^a   Wu, Lee ^a   Pardoll, Drew ^a   Roden, Richard ^a   Hung, Chien Fu ^a   Wu, T C ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CD40 LIGAND; HLA DQ ANTIGEN; HLA DQB1 02 ANTIGEN; HLA DQB1 ANTIGEN; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PEPTIDE FRAGMENT; UNCLASSIFIED DRUG;

ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX EPITHELIUM; ANIMAL; B LYMPHOCYTE; CELL STRAIN 3T3; EPITHELIUM CELL; GENETIC TRANSFECTION; GENETICS; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; MOUSE; PATHOLOGY; REFERENCE VALUE; VIROLOGY;

3T3 CELLS; ANIMALS; B-LYMPHOCYTES; CARCINOMA, SQUAMOUS CELL; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; EPITHELIAL CELLS; HISTOCOMPATIBILITY TESTING; HLA-DQ ANTIGENS; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICE; ONCOGENE PROTEINS, VIRAL; PEPTIDE FRAGMENTS; REFERENCE VALUES; TRANSFECTION;

EID: 34247882038     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2916     Document Type: Article

References (23)

1. Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat Rev Cancer 2006;6:753-63.
2. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
3. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50.
4. Tomson TT, Roden RB, Wu TC. Human papillomavirus vaccines for the prevention and treatment of cervical cancer. Curr Opin Investig Drugs 2004;5:1247-61.
5. Roden RB, Ling M, Wu TC. Vaccination to prevent and treat cervical cancer. Hum Pathol 2004;35:971-82.
6. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997;15:617-48.
7. Moniz M, Ling M, Hung CF, Wu TC. HPV DNA vaccines. Front Biosci 2003;8:d55-68.
8. Pardoll DM, Beckerleg AM. Exposing the immunology of naked DNA vaccines. Immunity 1995;3:165-9.
9. Robinson HL, Torres CA. DNA vaccines. Semin Immunol 1997;9:271-83.
10. Shedlock DJ, Weiner DB. DNA vaccination: antigen presentation and the induction of immunity. J Leukoc Biol 2000;68:793-806.
11. + T-cell immunity against early antigens E2 and E6. Cancer Res 2004;64:5449-55.
12. de Jong A, van der Burg SH, Kwappenberg KM, et al. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 2002;62:472-9.
13. Nakagawa M, Kim KH, Gillam TM, Moscicki AB. HLA class I binding promiscuity of the CD8 T-cell epitopes of the human papillomavirus type 16 E6 protein. J Virol 2007;1412-23.
14. + T-helper 1 immunity in relation to health versus disease. Int J Cancer 2006;118:950-6.
15. van Poelgeest MI, Nijhuis ER, Kwappenberg KM, et al. Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia. Int J Cancer 2006;118:675-83.
16. Trimble CL, Piantadosi S, Gravitt P, et al. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res 2005;11:4717-23.
17. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol 1998;36:3020-7.
18. Schultze JL, Michalak S, Seamon MJ, et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997;100:2757-65.
19. Gerard CM, Baudson N, Kraemer K, Ledent C, Pardoll D, Bruck C. Recombinant human papillomavirus type 16 E7 protein as a model antigen to study the vaccine potential in control and E7 transgenic mice. Clin Cancer Res 2001;7:838-47s.
20. de Gruijl TD, Bontkes HJ, Walboomers JM, et al. Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study. Cancer Res 1998;58:1700-6.
21. van der Burg SH, Ressing ME, Kwappenberg KM, et al. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer 2001;91:612-8.
22. Warrino DE, Olson WC, Knapp WT, et al. Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes. Clin Cancer Res 2004;10:3301-8.
23. Kadish AS, Timmins P, Wang Y, et al. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev 2002;11:483-8.